Salus Therapeutics Overview
- Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$14.1M
Salus Therapeutics General Information
Description
Developer of drugs based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The company's drugs include antisense, small interfering RNAs and delivery systems for DNA/RNA-based drugs.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Genta
Primary Office
- University Research Park
- 615 Arapeen Drive, Suite 102
- Salt Lake City, UT 84108
- United States
Salus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 21-Aug-2003 | $14.1M | 00.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
| 4. Later Stage VC | 01-Jun-2003 | 00000 | 00.00 | Completed | Clinical Trials - Phase 2 | |
| 3. Early Stage VC (Series B) | 01-Jun-2002 | 00.00 | 00.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | $1.2M | Completed | ||||
| 1. Seed Round | 01-Jul-1999 | $1.2M | Completed | Startup |
Salus Therapeutics Patents
Salus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2003223619-A1 | Antiviral phosphorothioate oligonucleotides | Inactive | 13-May-2002 | 00000000000 |
Salus Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| EPIC Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Pelion Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Signal Peak Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |